Company
WhiteLab Genomics
- AI
- Biotech
- Founded:
- 2019
- Location:
- Evry-Courcouronnes, France
- Funding:
- $26M · Series B · Oct 2026
Description
WhiteLab Genomics builds AI-driven computational platforms to design and optimize genomic medicines, producing in‑silico modules and predictive models used by drug developers and biopharma partners to de-risk R&D.
Related
Isomorphic LabsIsomorphic Labs uses machine learning to transform drug discovery by building predictive and generative AI models for designing molecules…
Bytelab SolutionsBuilds computational chemistry software and in silico testing tools for R&D teams; used by specialty-chemicals researchers and enterprises…
Qubit PharmaceuticalsQubit Pharmaceuticals develops quantum- and AI-driven molecular modeling platforms and drug discovery tools used to design novel drug…
Exvai ResearchExvai Research builds AI-driven quantitative research and investment solutions for financial markets, producing models and tools to help…
In&motionIn&motion builds intelligent wearable airbag systems using predictive algorithms for motorcycling, horse riding and skiing; products…
IktosIktos builds generative AI and robotics systems for drug discovery, producing platforms for de novo molecule design, retrosynthesis…
ScientaLabScientaLab develops a foundation model that predicts human immune response in immunology and inflammation, using multi-disease,…
LabGenius TherapeuticsLabGenius Therapeutics builds ML-driven discovery and optimisation for therapeutic antibodies, providing the EVA™ platform to design, test…
Hoxton FarmsHoxton Farms builds cultivated animal fat for food manufacturers and culinary customers using modular cultivators and AI-driven models to…
Timeline
Funding Roundwhitelabgx.com ↗
WhiteLab Genomics raises $26 million to build AI-designed bio-assets for the next generation Genomic MedicinesPress ReleasesOctober 6, 2026ScrollWhiteLab Genomics, a TechBio company using artificial intelligence to design genomic medicines, announced the close of a $26 million Series B financing led by AVP, with participation from new investors Yaday Health and Blast Club joining existing investors Omnes Capital and Debiopharm Innovation Fund.